Vanda Pharmaceuticals (VNDA) Projected to Post Earnings on Thursday

Vanda Pharmaceuticals (NASDAQ:VNDA) is anticipated to announce its earnings results before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $52.25 million for the quarter.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA opened at $4.69 on Friday. The stock has a 50 day simple moving average of $4.66 and a 200 day simple moving average of $4.92. Vanda Pharmaceuticals has a 52-week low of $3.61 and a 52-week high of $6.75. The firm has a market capitalization of $273.47 million, a PE ratio of -16.75 and a beta of 0.74.

Insider Activity at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the company’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the sale, the director now directly owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 8.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday. StockNews.com assumed coverage on Vanda Pharmaceuticals in a report on Wednesday. They set a “hold” rating for the company.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.